Patent · US Active

Combination product for prophylaxis and treatment of irritable bowel syndrome

US11400123B2 · kind B2 · utility

0Cited by

3References

18Claims

0Family size

Assignee

PrecisionBiotics Group Limited · IE

Inventors

Barry Kiely · Cork, IE
Eileen Frances Murphy · Cork, IE
David GROEGER · Cork, IE

Key dates

Filing date	Jan 29, 2019
Grant date	Aug 2, 2022
Priority date	—
Expiry date	Jan 29, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K45/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A combination product comprising an isolated strain of Bifidobacterium NCIMB 41003 and another strain which does not adversely interact with Bifidobacterium NCIMB 41003 improves gastrointestinal symptoms associated with IBS and improves one or more of mood, stress, anxiety, sleep quality and depression associated with IBS.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.